> Pharmaceutical Litigation > Aricept 23
Aricept originally came on the market as a 10 mg dosage drug to treat Alzheimerâ€™s disease. With their patent about to expire in 2010, Aricept’s manufacturer, Eisai, released a new version of the drug: Aricept 23.
Aricept 23 is the same formulation, but the dose is higher: 23 mg. Because of this, the FDA granted Eisai a 3-year extension on their patent. That meant 3 more years without competition from generic brands.
This change carried little added benefit to Alzheimerâ€™s patients and their families, yet it meant an increase in serious, life-threatening risks. While the trials of Aricept 23 showed some improvement in cognition â€“ although no real improvement in day-to-day functioning â€“ they also demonstrated a significant increase in nausea and vomiting.
Severe and frequent vomiting may lead to:
These complications can be fatal.
Aricept 23 is an example of a drug company putting profit above the safety of patients. If your loved one has been injured or lost their life after taking Aricept 23, you deserve compensation for your loss. The attorneys at the Law Offices of Brian D. Witzer are dedicated to seeking justice for those harmed by Aricept 23.
Contact us today by calling (888) WITZER-6 for a free, no-obligation consultation.